Industrielles, Paris. Mr. Barthelemys qualifications to sit on the Companys Board of Directors include his extensive experience in the bioprocessing field, including large scale
biologics manufacturing and commercialization of consumables used in bioprocessing.
Glenn L. Cooper, M.D.
has served as a director
of Repligen since August 2009. Dr. Cooper served as Executive Chairman of Coronado BioSciences, Inc. from 2010 to 2012. Prior to that, Dr. Cooper served as the Chairman and Chief Executive Officer of Indevus Pharmaceuticals, Inc., a
specialty pharmaceutical company focused on urology and endocrinology, from 2000 to 2009 and as Chief Executive Officer and Director from 1993 to 2000. Prior to joining Indevus in 1993, Dr. Cooper held numerous executive level positions
including President and Chief Executive Officer of Progenitor, Inc., Executive Vice President and Chief Operating Officer of Sphinx Pharmaceuticals Corporation, and various clinical and regulatory positions with Eli Lilly and Company.
Dr. Cooper has participated in the development, approval and commercialization of numerous drugs including Prozac
®
, Axid
®
, Lorabid
®
, Ceclor
®
, SANCTURA
®
, SANCTURA
XR
®
,
Supprelin-LA
®
and Vantas
®
.
Dr. Cooper received an M.D. from Tufts University School of Medicine, performed his postdoctoral training in Internal Medicine and Infectious Diseases at the New England Deaconess Hospital and the Massachusetts General Hospital and received a
B.A. from Harvard College. Dr. Cooper also serves as the Chairperson of the board of directors of Lascaux Media, LLC, a privately-held company. Dr. Coopers qualifications to sit on the Board of Directors of the Company include his
leadership roles at pharmaceutical companies.
John G. Cox
has served as a director of Repligen since November 2013. Mr. Cox
was most recently the CEO of Bioverativ Inc., a company which spun out of Biogen, Inc. in 2017, was publicly-traded and was then acquired by Sanofi in February 2018. Previously, he was the Executive Vice President of Pharmaceutical
Operations & Technology at Biogen Inc., a position he held since June 2010. Mr. Cox has also served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Vice President of
Manufacturing & General Manager of Biogens operations in Research Triangle Park, North Carolina, and Director of Manufacturing. Mr. Cox joined Biogen in 2003 as Director of Manufacturing Sciences. Before joining Biogen from 2000
to 2003, Mr. Cox held a number of senior operational roles at biotech contract manufacturer Covance/Diosynth where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth LLC
from 1993 to 2000. He currently serves as Executive Chairman at Torque Therapeutics, a cellular immuno-oncology company. Mr. Cox holds an MBA from the University of Michigan, an M.S. in Cell Biology from California State University and a B.S.
in Biology from Arizona State University. Mr. Coxs qualifications to sit on the Companys Board of Directors include his extensive experience in biopharmaceutical manufacturing and as a biopharmaceutical executive.
Karen A. Dawes
, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of
Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporations U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior
Vice President, Global Strategic Marketing, at Wyeth, a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial
Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that companys initial commercialization strategy to launch BeneFIX
®
and
Neumega
®
. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President,
Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol
®
/Glucotrol XL
®
, Zoloft
®
, and Cardura
®
. Ms. Dawes also serves as a member on the board of directors of Assertio Therapeutics, Inc. and Medicines360.
Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes qualifications to sit on the Companys Board of Directors include her extensive
strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.
Glenn P. Muir
has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director
role, including 26 years with Hologic, Inc., a large multi-national medical device and
10